What Intaflam Treats: Main Uses and Benefits

Intaflam is commonly used in situations involving certain distressing symptoms where additional symptomatic support is needed. This therapeutic approach is considered relevant for the short-term treatment of mild to moderate pain in adults.

The medication is applied across domains where additional symptomatic support is needed, and is commonly used to help with symptoms related to inflammatory or irritative states. It is relevant for easing discomfort from common acute and episodic manifestations, including dental pain, general headache, muscular aches, backache, and primary dysmenorrhea (menstrual pain).

It is also helpful in situations where multiple symptoms occur together, particularly those related to systemic imbalance seen with colds and flu. It is commonly used to help with symptoms such as elevated body temperature (fever) alongside generalized aches and systemic malaise. By easing this symptom burden, it contributes to improved comfort during periods of heightened symptoms and supports general well-being during symptomatic phases.

---

Quick Fact: Relief for Mild to Moderate Acute Pain and Fever

The combination supports patients during episodes of heightened discomfort by addressing both symptoms related to physical discomfort and symptoms related to inflammatory or irritative states.

Intaflam contains a combination of two active ingredients, ibuprofen (an NSAID) and paracetamol (acetaminophen), and its use is strictly determined by official regulatory guidelines, which define groups who are eligible and those for whom use is contraindicated.

Populations for Whom Use is Contraindicated

Use of this medicine is strictly prohibited for individuals with the following official regulatory contraindications:

• A documented history of hypersensitivity or allergic reactions (such as asthma, urticaria, or anaphylaxis) after taking ibuprofen, paracetamol, or other Non-Steroidal Anti-inflammatory Drugs (NSAIDs).
• Active or history of peptic ulceration, gastrointestinal bleeding, or perforation related to prior NSAID use.
• Severe, uncompensated heart failure (e.g., NYHA Class IV), severe liver disease/failure, or severe kidney disease/failure.
• During the third trimester of pregnancy (at or after 30 weeks gestation), and use should generally be avoided from 20 weeks gestation onward.
• Simultaneous use of any other products containing paracetamol or other NSAIDs.

Age and Restricted Use

• The use of most adult formulations is not recommended for children under 12 years of age.
• Elderly persons are advised to use the medication with caution due to an increased risk of serious gastrointestinal side effects.

Regulatory agencies establish these constraints to manage the specific risks associated with each component of the fixed-dose combination, emphasizing that individuals with these conditions must not use Intaflam.

Interactions with other medicines and products

Official regulatory information for Intaflam, a combination product of Ibuprofen and Paracetamol, establishes specific restrictions and documented interaction patterns with other substances.

---

Official Prohibitions and Contraindicated Co-administration

Co-administration with other medicinal products containing Paracetamol or Ibuprofen is strictly prohibited to prevent the risk of overdose and subsequent hepatotoxicity or other severe adverse effects. The combination is also contraindicated with other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), including COX-2 inhibitors, and Acetylsalicylic acid (Aspirin) at doses exceeding 75 mg daily, due to a heightened risk of gastrointestinal (GI) bleeding and ulceration.

---

Pharmacodynamic and Exposure Alterations

• Anticoagulants and Antiplatelet agents: Co-administration with drugs like Warfarin increases the risk of bleeding through a pharmacodynamic effect on platelet function.
• Blood Pressure Medications: The Ibuprofen component may reduce the therapeutic effect of Diuretics, ACE Inhibitors, and Angiotensin II Receptor Antagonists (ARBs).
• Exposure Alteration: Use with Lithium, Digoxin, or Phenytoin may result in increased plasma concentrations of these co-administered drugs by reducing their renal clearance. Similarly, Methotrexate toxicity risk is increased at doses of 15 mg/week or higher.
• Metabolic Inhibitors: Co-administration with CYP2C9 inhibitors (e.g., Fluconazole) may increase the systemic exposure of Ibuprofen.

---

Timing and Substance Constraints

• Timing: For patients taking low-dose Aspirin (leq 75 mg) for cardioprotection, regulatory guidance advises spacing the administration of Intaflam apart to minimize interference with Aspirin’s antiplatelet action. Colestyramine reduces Paracetamol absorption and may require timed separation.
• Alcohol: Consumption of Alcohol is associated with an increased risk of hepatotoxicity from the Paracetamol component and heightened risk of GI bleeding from the Ibuprofen component.

---

Population-Specific Interaction Notes

Regulatory documents note that the risk of interactions, particularly with Diuretics/ACE Inhibitors/ARBs, is magnified in elderly patients and those with existing renal, cardiac, or hepatic impairment.

How Intaflam Works

Intaflam's mechanism relies on the complementary action of its two active components, targeting distinct areas of the nociceptive and fever pathways to produce a dual-pathway physiological response.

Dual Modulation of Signaling Pathways

The Ibuprofen component acts primarily by inhibiting the Cyclooxygenase (COX) enzymes (COX -1 and COX -2). This action reduces the generation of prostaglandins—local mediators that sensitize nerve endings—thus limiting the initial physiological signal transmission. Meanwhile, Paracetamol's central mechanism involves a metabolite, AM404, which modulates TRPV1 and CB1 receptors in the central nervous system (CNS), effectively potentiating the body's natural descending inhibitory signaling.

️ Hypothalamic Thermoregulation

The Paracetamol component also exerts its effect directly on the brain's temperature control center, the Hypothalamus. By reducing PGE2 synthesis in this area, the drug helps reset the core body temperature set-point to a different level. This physiological adjustment promotes heat dissipation, such as through increased peripheral blood flow, resulting in the adjustment of thermal regulation.

Mechanistic Constraints

The combination utilizes complementary mechanistic actions by simultaneously targeting the site of peripheral prostaglandin synthesis via COX inhibition and enhancing central nociceptive signal modulation. However, the COX mechanism of Paracetamol is generally considered to have minimal functional peripheral anti-inflammatory action due to constraints imposed by the chemical environment at tissue sites.

Intaflam contains Ibuprofen and Paracetamol (Acetaminophen), a combination used to manage mild to moderate pain, inflammation, and fever. It is crucial to follow the directions provided by your healthcare professional and the instructions on the product label exactly. Do not exceed the prescribed dose or duration of treatment, as this may increase the risk of serious side effects, including liver and kidney damage, and gastrointestinal bleeding.

General Administration

• Dosage: The dosage will be determined by a healthcare provider based on the patient's age, weight (especially for children’s suspension), and the severity of the condition being treated. The lowest effective dose should be used for the shortest necessary duration.
• With Food: It is generally recommended to take Intaflam with food or milk. This may help to minimize the possibility of gastrointestinal upset, such as stomach pain or heartburn.
• Forms: If using the oral suspension, shake the bottle well before measuring the dose with a proper measuring device, such as an oral syringe or dosing cup. If taking tablets, swallow them whole with a full glass of water; do not crush, chew, or break tablets unless instructed otherwise.

Important Considerations

• Combination Products: Do not take Intaflam simultaneously with any other medication containing paracetamol or any other NSAID (Non-Steroidal Anti-Inflammatory Drug), including high-dose aspirin, as this increases the risk of overdose and adverse reactions.
• Missed Dose: If a dose is missed, take it as soon as you remember, unless it is nearly time for your next scheduled dose. In that case, skip the missed dose and continue with your regular schedule. Do not take a double dose to compensate for the missed one.
• When to Consult a Doctor: Seek medical advice if symptoms persist, worsen, or if you experience any signs of an allergic reaction, stomach pain, or unusual bleeding while using this medication.

Intaflam: Recent Clinical Evidence

---

Evidence for Use in Acute Pain Models

The primary evidence base for the Ibuprofen and Paracetamol combination relies on short-term Randomized Controlled Trials (RCTs) and meta-analyses. These studies explore outcomes related to physical discomfort following acute events, such as post-operative dental pain. Findings describe patterns where measurements of pain relief were assessed against the individual components alone. However, follow-up durations were limited, meaning data for other acute pain contexts is less characterized, and long-term effects are not fully established.

---

Evidence for Use in Headache and Acute Musculoskeletal Pain

Research was also observed in contexts involving episodic changes associated with headache, where studies explored measurements related to the time to onset of relief. For acute musculoskeletal pain, data show patterns related to symptom change, but in some studies, differences compared directly to monotherapy were not statistically significant. The design and results of studies exploring short-term symptom changes exhibit variability, and comparative evidence is lacking in some contexts.

---

Evidence for Use in Fever

The combination was evaluated in clinical studies assessing short-term fever patterns in both adult and pediatric populations. The research examined outcomes related to systemic or functional imbalance, such as body temperature reduction. Findings describe patterns where the duration of the antipyretic action was monitored against established standards. However, comparative evidence is lacking when assessed against the practice of alternating the two single-ingredient medicines.

---

Long-Term Studies and Uncertainty

The research focus aligns with the indication for short-term use only. Studies that monitored patients over an intermediate duration (e.g., 10 to 13 weeks) were primarily exploratory, intended to collect safety data rather than demonstrate sustained efficacy. Consequently, certainty remains low for the combination's use in chronic or maintenance pain management, as the existing data are exploratory and follow-up durations were limited across most acute pain studies.

Key Studies & References

1. Fixed-dose combination of Ibuprofen and Paracetamol for Musculoskeletal and Soft Tissue Pain: A Narrative Review of Trial Data

Common questions about Intaflam (FAQ)

Q: Does this medication make you sleepy?

A: Official regulatory documents indicate that drowsiness or somnolence may be experienced, as it is a side effect reported due to the anticholinergic properties of doxylamine succinate, one of the components. Official labeling indicates that combining this medication with alcohol or other central nervous system depressants may lead to increased drowsiness.

Q: Can I take it for migraines?

A: The medication is approved for a specific indication (e.g., nausea and vomiting in pregnancy) and is not indicated for migraine treatment. Regulatory documents do note that migraines have been reported as an adverse event in people taking the medication after it was approved for general use. This information is based on post-approval data collected by regulatory authorities.

Q: Can children 2 years old use it?

A: The official product label indicates the approved use in specific patient populations. If this age group is not included in the approved pediatric subpopulation, the official product label does not contain information regarding its safety or effectiveness for children 2 years old. The approved age range can be found in the 'Who can and cannot use Intaflam?' section.

Storage and Environmental Requirements

Intaflam must be stored strictly according to the conditions defined in the official labeling to maintain its stability. Regulatory documents require the product to be stored at a temperature below 30°C (86°F), or in some cases, below 25°C (77°F), in a cool and dry place. It is mandatory that the medicine be protected from light and kept from freezing.

Packaging and Safety Rules

To ensure product integrity, the medicine should be kept in its original container and must always be stored out of the sight and reach of children.

Official Disposal Instructions

Unused or expired Intaflam should not be disposed of in household trash or via wastewater. Official guidance instructs users to ask a pharmacist or healthcare professional about approved drug take-back programs or collection points for safe disposal.